Srinivas Murthy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6929982/publications.pdf

Version: 2024-02-01

		29994	6630
169	31,194	54	156
papers	citations	h-index	g-index
196	196	196	50961
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
2	Repurposed Antiviral Drugs for Covid-19 â€" Interim WHO Solidarity Trial Results. New England Journal of Medicine, 2021, 384, 497-511.	13.9	2,014
3	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically III Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1330.	3.8	1,855
4	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589
5	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	13.9	1,419
6	A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases, The, 2020, 20, e192-e197.	4.6	1,165
7	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infectious Diseases, The, 2018, 18, 1191-1210.	4.6	1,084
8	A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infectious Diseases, The, 2022, 22, e102-e107.	4.6	1,068
9	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	4.9	1,064
10	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infectious Diseases, The, 2018, 18, 1211-1228.	4.6	862
11	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	13.9	778
12	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	6.3	740
13	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	6.3	716
14	Therapeutic Anticoagulation with Heparin in Critically III Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	13.9	712
15	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	3.8	671
16	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
17	Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ, The, 2020, 370, m2980.	3.0	592
18	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573

#	Article	IF	Citations
19	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	6.3	571
20	Care for Critically III Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 323, 1499.	3.8	564
21	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
22	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
23	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
24	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
25	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine, the, 2019, 7, 69-89.	5.2	326
26	Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov. Annals of Internal Medicine, 2010, 153, 158.	2.0	299
27	Intensive Care Unit Capacity in Low-Income Countries: A Systematic Review. PLoS ONE, 2015, 10, e0116949.	1.1	255
28	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Tj ETQq0 0 (O rgBT /Ov	erlock 10 Tf 5
29	COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Medicine, 2020, 46, 833-836.	3.9	222
30	Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 1061-1082.	4.9	221
31	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	5 . 8	194
32	Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	3.8	169
33	Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Intensive Care Medicine, 2017, 43, 612-624.	3.9	140
34	Les canules nasales à haut débit pour le traitement de l'insuffisance respiratoire hypoxémique aiguë chez les patients atteints de la COVID-19: comptes rendus systématiques de l'efficacité et des risques d'aérosolisation, de dispersion et de transmission de l'infection. Canadian Journal of Anaesthesia, 2020, 67, 1217-1248.	0.7	139
35	Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review. Critical Care, 2012, 16, R7.	2.5	118
36	Ebola Virus Disease among Children in West Africa. New England Journal of Medicine, 2015, 372, 1274-1277.	13.9	118

#	Article	IF	Citations
37	Pediatric Versus Adult Drug Trials for Conditions With High Pediatric Disease Burden. Pediatrics, 2012, 130, 285-292.	1.0	115
38	Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017. Lancet Infectious Diseases, The, 2020, 20, 37-59.	4.6	104
39	Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Cmaj, 2022, 194, E242-E251.	0.9	103
40	Ebola virus disease and critical illness. Critical Care, 2016, 20, 217.	2.5	97
41	Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. Lancet Infectious Diseases, The, 2020, 20, 60-79.	4.6	95
42	Clinical review: International comparisons in critical care - lessons learned. Critical Care, 2012, 16, 218.	2.5	90
43	Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet, The, 2018, 391, 700-708.	6.3	89
44	Global Health Care of the Critically Ill in Low-Resource Settings. Annals of the American Thoracic Society, 2013, 10, 509-513.	1.5	86
45	Remdesivir for severe covid-19: a clinical practice guideline. BMJ, The, 2020, 370, m2924.	3.0	86
46	New filovirus disease classification and nomenclature. Nature Reviews Microbiology, 2019, 17, 261-263.	13.6	84
47	Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	3.8	83
48	Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ, The, 2021, 373, n949.	3.0	78
49	Network Analysis of Transcriptional Responses Induced by Mesenchymal Stem Cell Treatment of Experimental Sepsis. American Journal of Pathology, 2012, 181, 1681-1692.	1.9	76
50	Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 1122-1129.	0.7	72
51	Outcomes for patients with COVID‶9 admitted to Australian intensive care units during the first four months of the pandemic. Medical Journal of Australia, 2021, 214, 23-30.	0.8	70
52	A national cross-sectional survey of public perceptions of the COVID-19 pandemic: Self-reported beliefs, knowledge, and behaviors. PLoS ONE, 2020, 15, e0241259.	1.1	69
53	Coronavirus Disease 2019 in Critically Ill Children: A Narrative Review of the Literature*. Pediatric Critical Care Medicine, 2020, 21, 662-666.	0.2	65
54	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	3.9	65

#	Article	IF	CITATIONS
55	Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ, The, 2021, 374, n2231.	3.0	59
56	Access to urban acute care services in high- vs. middle-income countries: an analysis of seven cities. Intensive Care Medicine, 2014, 40, 342-352.	3.9	57
57	Pregnancy and <scp>COVID</scp> â€19: pharmacologic considerations. Ultrasound in Obstetrics and Gynecology, 2021, 57, 195-203.	0.9	57
58	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical Trials, 2020, 17, 491-500.	0.7	56
59	Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clinical Microbiology and Infection, 2022, 28, 1203-1210.	2.8	50
60	Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. CMAJ Open, 2021, 9, E181-E188.	1.1	49
61	Misinformation During the Coronavirus Disease 2019 Outbreak: How Knowledge Emerges From Noise. , 2020, 2, e0098.		46
62	Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. Cmaj, 2020, 192, E536-E545.	0.9	45
63	Restricted visitation policies in acute care settings during the COVID-19 pandemic: a scoping review. Critical Care, 2021, 25, 347.	2.5	45
64	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	1.2	44
65	A survey on the resources and practices in pediatric critical care of resource-rich and resource-limited countries. Journal of Intensive Care, 2015, 3, 40.	1.3	43
66	Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, The, 2020, 20, 770-772.	4.6	40
67	The importance of airway and lung microbiome in the critically ill. Critical Care, 2020, 24, 537.	2.5	36
68	Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. Cmaj, 2020, 192, E405-E407.	0.9	36
69	How to Use and Interpret the Results of a Platform Trial. JAMA - Journal of the American Medical Association, 2022, 327, 67.	3.8	36
70	Early vasopressor use following traumatic injury: a systematic review. BMJ Open, 2017, 7, e017559.	0.8	33
71	Pediatric Emergency and Critical Care Resources and Infrastructure in Resource-Limited Settings: A Multicountry Survey*. Critical Care Medicine, 2021, 49, 671-681.	0.4	33
72	Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. ERJ Open Research, 2022, 8, 00552-2021.	1.1	33

#	Article	IF	Citations
73	Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. BMC Infectious Diseases, 2019, 19, 376.	1.3	30
74	Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. Trials, 2020, 21, 734.	0.7	30
75	Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic. Journal of Global Antimicrobial Resistance, 2021, 25, 5-7.	0.9	27
76	Longitudinal Plasma Proteomics Analysis Reveals Novel Candidate Biomarkers in Acute COVID-19. Journal of Proteome Research, 2022, 21, 975-992.	1.8	27
77	IL-6 blockade for COVID-19: a global scientific call to arms. Lancet Respiratory Medicine,the, 2021, 9, 438-440.	5.2	25
78	Non-invasive ventilation in children and adults in low- and low-middle income countries: A systematic review and meta-analysis. Journal of Critical Care, 2018, 47, 310-319.	1.0	24
79	Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov. PLoS ONE, 2012, 7, e28820.	1.1	24
80	Operationalisation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 trials in a low and lower-middle income critical care learning health system Wellcome Open Research, 2021, 6, 14.	0.9	23
81	Infectious Diseases Following Disasters. Disaster Medicine and Public Health Preparedness, 2010, 4, 232-238.	0.7	21
82	An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients. Critical Care, 2021, 25, 199.	2.5	21
83	Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013. Health Research Policy and Systems, 2015, 13, 28.	1.1	20
84	Barriers to supportive care during the Ebola virus disease outbreak in West Africa: Results of a qualitative study. PLoS ONE, 2018, 13, e0201091.	1.1	19
85	Moral Distress and Other Wellness Measures in Canadian Critical Care Physicians. Annals of the American Thoracic Society, 2021, 18, 1343-1351.	1.5	19
86	Leveraging a Cloud-Based Critical Care Registry for COVID-19 Pandemic Surveillance and Research in Low- and Middle-Income Countries. JMIR Public Health and Surveillance, 2020, 6, e21939.	1.2	18
87	Outpatient Therapies for COVID-19: How Do We Choose?. Open Forum Infectious Diseases, 2022, 9, ofac008.	0.4	18
88	The Potential Harm of Cytomegalovirus Infection in Immunocompetent Critically Ill Children. Frontiers in Pediatrics, 2018, 6, 96.	0.9	17
89	Prevalence of Acute Rehabilitation for Kids in the PICU: A Canadian Multicenter Point Prevalence Study*. Pediatric Critical Care Medicine, 2021, 22, 181-193.	0.2	17
90	Ebola and provision of critical care. Lancet, The, 2015, 385, 1392-1393.	6.3	16

#	Article	IF	Citations
91	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. PLoS ONE, 2022, 17, e0270668.	1.1	16
92	Mortality Risk Using a Pediatric Quick Sequential (Sepsis-Related) Organ Failure Assessment Varies With Vital Sign Thresholds*. Pediatric Critical Care Medicine, 2018, 19, e394-e402.	0.2	15
93	Quality and capacity indicators for hospitalized pediatric oncology patients with critical illness: A modified delphi consensus. Cancer Medicine, 2020, 9, 6984-6995.	1.3	15
94	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors. CJC Open, 2021, 3, 965-975.	0.7	15
95	Pediatric sepsis and septic shock management in resource-limited settings. Intensive Care Medicine, 2016, 42, 2037-2039.	3.9	14
96	Infections of the Developing World. Critical Care Clinics, 2013, 29, 485-507.	1.0	12
97	Design and α-testing of an electronic rounding tool (CERTAINp) to improve process of care in pediatric intensive care unit. Journal of Clinical Monitoring and Computing, 2017, 31, 1313-1320.	0.7	12
98	Core outcome set in paediatric sepsis in low- and middle-income countries: a study protocol. BMJ Open, 2020, 10, e034960.	0.8	12
99	Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110521.	0.6	12
100	Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. Scientific Reports, 2022, 12, 6843.	1.6	12
101	Global infectious disease research collaborations in crises: building capacity and inclusivity through cooperation. Globalization and Health, 2021, 17, 84.	2.4	11
102	Clinical trials in COVID-19 management & Drevention: A meta-epidemiological study examining methodological quality. Journal of Clinical Epidemiology, 2021, 139, 68-79.	2.4	11
103	The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics. Clinical Pharmacology and Therapeutics, 2012, 91, 685-691.	2.3	10
104	Effectiveness of a Daily Rounding Checklist on Processes of Care and Outcomes in Diverse Pediatric Intensive Care Units Across the World. Journal of Tropical Pediatrics, 2021, 67, .	0.7	10
105	Characteristics and Timing of Mortality in Children Dying With Infections in North American PICUs*. Pediatric Critical Care Medicine, 2021, 22, 365-379.	0.2	10
106	Stimulating severe COVID-19: the potential role of GM-CSF antagonism. Lancet Respiratory Medicine, the, 2022, 10, 223-224.	5.2	10
107	Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC–WHO clinical characterisation protocol. PLoS Medicine, 2022, 19, e1003969.	3.9	10
108	Renin-Angiotensin System Pathway Therapeutics Associated With Improved Outcomes in Males Hospitalized With COVID-19*. Critical Care Medicine, 2022, 50, 1306-1317.	0.4	10

#	Article	IF	CITATIONS
109	Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe, The, 2022, 3, e683-e692.	3.4	10
110	Analysis of Pediatric Clinical Drug Trials for Neuropsychiatric Conditions. Pediatrics, 2013, 131, 1125-1131.	1.0	9
111	How Canada can better embed randomized trials into clinical care. Cmaj, 2020, 192, E928-E929.	0.9	9
112	COVID-19 infection prevention and control procedures and institutional trust: Perceptions of Canadian intensive care and emergency department nurses. Canadian Journal of Anaesthesia, 2021, 68, 1165-1175.	0.7	9
113	Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis. Critical Care, 2022, 26, 141.	2.5	9
114	Priorities, Barriers, and Facilitators towards International Guidelines for the Delivery of Supportive Clinical Care during an Ebola Outbreak: A Cross-Sectional Survey. Viruses, 2019, 11, 194.	1.5	8
115	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials, 2021, 22, 224.	0.7	8
116	Incorporating Adult Evidence Into Pediatric Research and Practice. JAMA - Journal of the American Medical Association, 2021, 325, 1937.	3.8	8
117	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open, 2020, 10, e040768.	0.8	7
118	Global PARITY: Study Design for a Multi-Centered, International Point Prevalence Study to Estimate the Burden of Pediatric Acute Critical Illness in Resource-Limited Settings. Frontiers in Pediatrics, 2021, 9, 793326.	0.9	7
119	External Validation of the "Quick―Pediatric Logistic Organ Dysfunction-2 Score Using a Large North American Cohort of Critically Ill Children With Suspected Infection. Pediatric Critical Care Medicine, 2018, 19, 1114-1119.	0.2	6
120	Pediatric Critical Care and the Climate Emergency: Our Responsibilities and a Call for Change. Frontiers in Pediatrics, 2020, 8, 472.	0.9	6
121	Stakeholder perspectives on adaptive clinical trials: a scoping review. Trials, 2020, 21, 539.	0.7	6
122	Canada, global vaccine supply, and the TRIPS waiver. Canadian Journal of Public Health, 2021, 112, 543-547.	1.1	6
123	Canada is no global health leader on COVID-19 vaccine equity. Lancet, The, 2021, 397, 1803.	6.3	6
124	Les immunoglobulines intraveineuses pour le choc septique : une enquête nationale canadienne auprès des médecins intensivistes et spécialistes des maladies infectieuses. Canadian Journal of Anaesthesia, 2021, 68, 782-790.	0.7	6
125	Impact of restricted visitation policies in hospitals on patients, family members and healthcare providers during the COVID-19 pandemic: a scoping review protocol. BMJ Open, 2021, 11, e048227.	0.8	6
126	Prediction Model Performance With Different Imputation Strategies: A Simulation Study Using a North American ICU Registry. Pediatric Critical Care Medicine, 2022, 23, e29-e44.	0.2	6

#	Article	IF	CITATIONS
127	Management of severe viral infections in the pediatric intensive care unit. Journal of Pediatric Intensive Care, 2015, 03, 205-216.	0.4	5
128	Risk of dispersion or aerosol generation and infection transmission with nasopharyngeal and oropharyngeal swabs for detection of COVID-19: a systematic review. BMJ Open, 2021, 11, e040616.	0.8	5
129	Vasopressor use following traumatic injury: protocol for a systematic review. BMJ Open, 2017, 7, e014166.	0.8	4
130	Infection Management in Patients with Sepsis and Septic Shock in Resource-Limited Settings. , 2019, , 163-184.		4
131	Pediatric Sepsis and Septic Shock Management in Resource-Limited Settings. , 2019, , 197-216.		4
132	Current Challenges in the Management of Sepsis in ICUs in Resource-Poor Settings and Suggestions for the Future., 2019, , 1-24.		4
133	Third-generation cephalosporin-resistant urinary tract infections in children presenting to the paediatric emergency department. Paediatrics and Child Health, 2020, 25, 166-172.	0.3	4
134	Data initiatives supporting critical care research and quality improvement in Canada: an environmental scan and narrative review. Canadian Journal of Anaesthesia, 2020, 67, 475-484.	0.7	4
135	Assessment of 28-Day In-Hospital Mortality in Mechanically Ventilated Patients With Coronavirus Disease 2019: An International Cohort Study., 2021, 3, e0567.		4
136	Data flow within global clinical trials: a scoping review. BMJ Global Health, 2022, 7, e008128.	2.0	4
137	Selective digestive decontamination in critically ill children: A survey of Canadian providers. Journal of Critical Care, 2017, 39, 169-171.	1.0	3
138	Perioperative antibiotics in pediatric cardiac surgery: protocol for a systematic review. Systematic Reviews, 2017, 6, 107.	2.5	3
139	Editorial: Pediatric Critical Care in Resource-Limited Settings. Frontiers in Pediatrics, 2019, 7, 80.	0.9	3
140	Critical care service delivery across healthcare systems in low-income and low-middle-income countries: protocol for a systematic review. BMJ Open, 2021, 11, e048423.	0.8	3
141	Clinician-researcher's perspectives on clinical research during the COVID19 pandemic. PLoS ONE, 2020, 15, e0243525.	1.1	3
142	Organ dysfunction and death in patients admitted to hospital with COVID-19 in pandemic waves 1 to 3 in British Columbia, Ontario and Quebec, Canada: a cohort study. CMAJ Open, 2022, 10, E379-E389.	1.1	3
143	After the FEAST—Fluid Resuscitation in Pediatric Sepsis. Indian Journal of Pediatrics, 2013, 80, 151-154.	0.3	2
144	Outcome Measures in Sepsis, Revisited*. Pediatric Critical Care Medicine, 2017, 18, 803-804.	0.2	2

#	Article	IF	CITATIONS
145	Training of Pediatric Critical Care Providers in Developing Countries in Evidence Based Medicine Utilizing Remote Simulation Sessions. Global Pediatric Health, 2021, 8, 2333794X2110074.	0.3	2
146	Hospital outcomes of children admitted to intensive care in British Columbia via interfacility transfer versus direct admission from 2015 to 2017: a descriptive analysis. CMAJ Open, 2021, 9, E602-E606.	1.1	2
147	Fungal infections should be part of the core outcome set for COVID-19 – Authors' reply. Lancet Infectious Diseases, The, 2021, 21, e146.	4.6	2
148	Critical Care in Low-Resource Settings. Respiratory Medicine, 2014, , 247-260.	0.1	2
149	Challenges and Opportunities for Implementing Pediatric Early Warning Systems in Low- and Middle-Income Countries—Using Resources Wisely. JAMA Network Open, 2022, 5, e221553.	2.8	2
150	The Young Investigator Retreat of the Canadian Critical Care Trials Group: mentorship and self-discovery. Canadian Journal of Anaesthesia, 2018, 65, 239-245.	0.7	1
151	Hyperferritinemia in Sepsis in Children. Pediatric Critical Care Medicine, 2018, 19, 692-693.	0.2	1
152	Clinical research networks and assessing pandemic severity. The Lancet Global Health, 2019, 7, e33.	2.9	1
153	Academic careers in global pulmonary and critical care medicine. Journal of Global Health, 2020, 10, 010313.	1.2	1
154	Épidémiologie de l'utilisation de l'immunoglobuline intraveineuse dans les cas de choc septiqueÂ: u analyse de cohorte rétrospective de la base de données Premier Healthcare. Canadian Journal of Anaesthesia, 2021, 68, 1641-1650.	ne 0.7	1
155	An Artificial Neural Network–Based Pediatric Mortality Risk Score: Development and Performance Evaluation Using Data From a Large North American Registry. JMIR Medical Informatics, 2021, 9, e24079.	1.3	1
156	Defining Optimal Empirical Antibiotic Regimens in a Rapidly Changing Landscape of Resistance. JAMA Network Open, 2020, 3, e1921150.	2.8	1
157	Establishing Healthcare Worker Performance and Safety in Providing Critical Care for Patients in a Simulated Ebola Treatment Unit: Non-Randomized Pilot Study. Viruses, 2021, 13, 2205.	1.5	1
158	Antimicrobial treatment duration for uncomplicated bloodstream infections in critically ill children: a multicentre observational study. BMC Pediatrics, 2022, 22, 179.	0.7	1
159	Noninferiority Margin Size and Acceptance of Trial Results: Contingent Valuation Survey of Clinician Preferences for Noninferior Mortality. Medical Decision Making, 2022, 42, 832-836.	1.2	1
160	Innominate artery aneurysm after cannulation for extracorporeal membrane oxygenation via the right carotid artery. Intensive Care Medicine, 2013, 39, 2038-2039.	3.9	0
161	Who Says There Is No "l―in Team? Achieving Individual Success in Collaborative Clinical Research in Critical Care. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 911-912.	2.5	0
162	Dopamine and the Risk for Hospital-Acquired Infections*. Pediatric Critical Care Medicine, 2018, 19, 269-270.	0.2	0

SRINIVAS MURTHY

#	Article	IF	CITATIONS
163	The authors reply. Pediatric Critical Care Medicine, 2020, 21, 783-784.	0.2	O
164	Cytomegalovirus in Pediatric Sepsis. Pediatric Critical Care Medicine, 2020, 21, 396-397.	0.2	0
165	Use of Neuromuscular Blocking Agents in Mechanically Ventilated Patients with COVID-19: A Propensity Score Analysis. SSRN Electronic Journal, 0, , .	0.4	0
166	The Effect of Funding Source on Outcome Reporting Among Drug Trials. Annals of Internal Medicine, 2011, 154, 138.	2.0	0
167	The authors reply. Pediatric Critical Care Medicine, 2020, 21, 1023.	0.2	0
168	The authors respond to "Concerns about subgroup analyses and reason for stopping remdesivir trial― Cmaj, 2022, 194, E390-E390.	0.9	0
169	Therapeutics for COVID-19. World Scientific Series in Global Healthcare Economics and Public Policy, 2022, , 223-248.	0.1	0